Ariad Pharmaceuticals: Advancing in Front of Phase 3 Interim Results

|
 |  Includes: ARIA, ASTX, CASC, CLNE, FSYS, GTXI, ONB, OSIR, PRXL, SPPI, SWC, TOMO, UNG
by: Justin M. Hall

The Lucky 13 Buys portfolio continues to advance.

In the past two sessions, some of the companies have seen a dramatic rise in their share prices. View the results from Friday, July 24 in this article.

As of the close on Tuesday, July 28, four companies are up over 30%. While seven of the 13 have achieved gains exceeding 20%, nine are above 10%.

Symbol
Last/NAV
%Gain/Loss
ARIA
2.80
85.43%
ONTY
4.40
37.07%
SUPG
2.70
33.00%
GTXI
10.58
30.46%
FSYS
23.98
28.79%
SWC
6.39
26.04%
ONB
11.33
20.92%
SPPI
6.75
19.89%
PRXL
14.44
14.33%
UNG
12.90
5.91%
TOMO
2.78
5.30%
CLNE
8.94
3.83%
OSIR
12.70
1.36%
Click to enlarge

Data is based on the closing prices on Tuesday July 7 to Tuesday July 27, 2009.

Ariad Pharmaceuticals (NASDAQ:ARIA) shares jumped following a significant Phase 1 clinical trial announcement and in front of much anticipated interim phase 3 results for the company’s cancer drug, ridaforolimus. An announcement is due any day. ARIA will report quarterly earnings on Thursday, July 30 at 4:15 PM ET. Investors can access the webcast here.

Spectrum Pharmaceuticals (NASDAQ:SPPI) continues its climb as investors anticipate the company’s two cancer drugs, Zevalin and Fusilev, will be approved on or before September 7 and October 8, 2009, respectively.

Old National Bank (NASDAQ:ONB) rose early this week on a positive quarterly earnings announcement.

Disclosure: Long ARIA and SPPI